187 related articles for article (PubMed ID: 34253581)
1. Non-invasive Detection of Immunotherapy-Induced Adverse Events.
Ferreira CA; Heidari P; Ataeinia B; Sinevici N; Sise ME; Colvin RB; Wehrenberg-Klee E; Mahmood U
Clin Cancer Res; 2021 Oct; 27(19):5353-5364. PubMed ID: 34253581
[TBL] [Abstract][Full Text] [Related]
2. The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging.
Larimer BM; Bloch E; Nesti S; Austin EE; Wehrenberg-Klee E; Boland G; Mahmood U
Clin Cancer Res; 2019 Feb; 25(4):1196-1205. PubMed ID: 30327313
[TBL] [Abstract][Full Text] [Related]
3. Granzyme B PET Imaging of Immune Checkpoint Inhibitor Combinations in Colon Cancer Phenotypes.
Goggi JL; Tan YX; Hartimath SV; Jieu B; Hwang YY; Jiang L; Boominathan R; Cheng P; Yuen TY; Chin HX; Tang JR; Larbi A; Chacko AM; Renia L; Johannes C; Robins EG
Mol Imaging Biol; 2020 Oct; 22(5):1392-1402. PubMed ID: 32705455
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
5. Granzyme B PET Imaging of the Innate Immune Response.
Capaccione KM; Doubrovin M; Bhatt N; Mintz A; Molotkov A
Molecules; 2020 Jul; 25(13):. PubMed ID: 32646038
[TBL] [Abstract][Full Text] [Related]
6. Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response.
LaSalle T; Austin EE; Rigney G; Wehrenberg-Klee E; Nesti S; Larimer B; Mahmood U
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461343
[TBL] [Abstract][Full Text] [Related]
7. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
8. Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer.
Goggi JL; Hartimath SV; Xuan TY; Khanapur S; Jieu B; Chin HX; Ramasamy B; Cheng P; Rong TJ; Fong YF; Yuen TY; Msallam R; Chacko AM; Renia L; Johannes C; Hwang YY; Robins EG
Mol Imaging Biol; 2021 Oct; 23(5):714-723. PubMed ID: 33713000
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
10. Examining Immunotherapy Response Using Multiple Radiotracers.
Goggi JL; Hartimath SV; Hwang Y; Tan YX; Khanapur S; Ramasamy B; Jiang L; Yong FF; Cheng P; Tan PW; Husaini MA; Yuen TY; Jieu B; Chacko AM; Larbi A; Renia L; Johannes C; Robins EG
Mol Imaging Biol; 2020 Aug; 22(4):993-1002. PubMed ID: 32006204
[TBL] [Abstract][Full Text] [Related]
11. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
[TBL] [Abstract][Full Text] [Related]
12. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
13. Testing Immune-Related Adverse Events in Cancer Immunotherapy.
Farmer JR
Clin Lab Med; 2019 Dec; 39(4):669-683. PubMed ID: 31668277
[TBL] [Abstract][Full Text] [Related]
14. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
15. Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.
Jacoberger-Foissac C; Blake SJ; Liu J; McDonald E; Triscott H; Nakamura K; Smyth MJ; Teng MW
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199513
[TBL] [Abstract][Full Text] [Related]
16. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
17. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
18. Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography.
Anderson MA; Kurra V; Bradley W; Kilcoyne A; Mojtahed A; Lee SI
Br J Radiol; 2021 Feb; 94(1118):20200663. PubMed ID: 33112648
[TBL] [Abstract][Full Text] [Related]
19. A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma.
Kato T; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya YU; Wang C; Hatano K; Kawashima A; Ujike T; Kawasaki K; Morii E; Gotoh K; Eguchi H; Kiyotani K; Fujita K; Nonomura N; Uemura M
Anticancer Res; 2020 Sep; 40(9):4875-4883. PubMed ID: 32878775
[TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
